{"schema_version":"secwatch.filing_event.v1","accession":"0000021076-25-000051","form_type":"8-K","ticker":"CLX","cik":"0000021076","company_name":"CLOROX CO /DE/","filed_at":"2025-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.609593+00:00","generated_at":"2026-05-17T00:58:24.615362+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Clorox Q1 FY2026: Net sales down 19% to $1.43B, adj. EPS $0.85 (-54% YoY) on ERP disruption","bullets":["Diluted EPS $0.65 vs $0.80 prior year; adjusted EPS $0.85 vs $1.86 (-54%), largely due to ERP transition.","Gross margin fell 410 bps to 41.7% on lower volume and higher manufacturing/logistics costs.","Organic sales declined 17%, with volume down 15%; Health & Wellness segment sales -19%.","Operating cash flow $93M vs $221M (-58%); free cash flow $57M vs $182M.","Company cites expected ERP transition impact; no specific numerical guidance revision provided."],"urls":{"canonical":"https://secwatch.observer/filing/0000021076-25-000051","json":"https://secwatch.observer/filing/0000021076-25-000051.json","markdown":"https://secwatch.observer/filing/0000021076-25-000051.md","text":"https://secwatch.observer/filing/0000021076-25-000051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/21076/000002107625000051/0000021076-25-000051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/21076/000002107625000051/clx-20251103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:58:24.615362+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}